In a new article published in the Journal of the National Cancer Institute, Moffitt Cancer Center researchers report that patients treated with immune checkpoint inhibitors have a higher self-reported quality of life than patients treated with other types of therapy.
The gut microbiome can impact us in a variety of different ways, from our metabolism to our mood. Now, NIBIB-funded researchers are investigating if a fiber-based gel can restore beneficial microbes in the gut to enhance the efficacy of immune checkpoint inhibitors, a type of cancer immunotherapy treatment, in mice.
A retrospective analysis of large datasets of biomarkers from tumors and healthy tissue by researchers at the Johns Hopkins Kimmel Cancer Center Convergence Institute suggests that older cancer patients could benefit as much as younger patients from cancer immunotherapies.
The National Cancer Institute (NCI) recently awarded Memorial Sloan Kettering Cancer Center (MSK) with a prestigious Specialized Programs of Research Excellence (SPORE) grant for leukemia research. The Translational Research Program (TRP) is the home of the SPOREs — a cornerstone of NCI’s efforts to promote collaborative, interdisciplinary translational cancer research.
The National Cancer Institute has renewed the Harold C. Simmons Comprehensive Cancer Center’s comprehensive designation, reaffirming its place among the country’s elite cancer institutes.
NCI-designated cancer centers, AACI members and other cancer centers and medical groups endorse HPV vaccination and cancer screening to eliminate cancers caused by the virus.
Infants whose mothers were obese during pregnancy may have a heightened risk of developing colorectal cancer later in life, according to new research led by public health experts at The University of Texas Health Science Center at Houston (UTHealth).
Cedars-Sinai Cancer researchers have discovered that intestinal microorganisms help regulate anti-tumor immune responses to radiation treatments, and that fungi and bacteria have opposing effects on those responses.
New research published today in JAMA Oncology reports how two separate DNA changes appear to predict aggressive childhood leukemias when they occur in combination. This study illuminates genetic understanding of acute lymphoblastic leukemia in children with the worst outcomes.
A new study from the Perelman School of Medicine at the University of Pennsylvania shows how to overcome resistance to CAR T cell therapy with an experimental small molecule inhibitor.
Combining a histone deacetylase inhibitor drug with immunotherapy agents is safe, and may benefit some patients with advanced cancers that have not responded to traditional therapy, according to results of a phase 1 clinical trial led by researchers at the Johns Hopkins Kimmel Cancer Center, Bloomberg~Kimmel Institute for Cancer Immunotherapy and several other centers including University of Pittsburgh Cancer Institute, Yale Cancer Center and City of Hope in Los Angeles, which participated in study enrollment, and the University of Southern California and University College Cork in Ireland, which collaborated on analysis of the data.
A two-arm molecule can effectively deplete cancer-protecting cells inside tumors, allowing the immune system to fight off tumors without becoming overactive. The finding, published online in Science Translational Medicine, could leaA two-arm molecule can effectively deplete cancer-protecting cells inside tumors, allowing the immune system to fight off tumors without becoming overactive. The finding, published online in Science Translational Medicine, could lead to new types of cancer immunotherapies.d to new types of cancer immunotherapies.
A Herbert Wertheim School of Public Health and Human Longevity Science at University of California San Diego clinical trial showed that graphic warning labels on cigarette packaging changes perceptions of smokers to recognize the negative consequences of tobacco and consider quitting.
In a new article published online ahead of print in the journal Cancer Research, Moffitt Cancer Center researchers demonstrate a link between the presence of cutaneous human papillomavirus and the incidence of squamous cell carcinomas and identify key characteristics of infection that may contribute to development of the disease.
Researchers led by the University of Michigan Rogel Cancer Center identified an inhibitor that showed promise against metastatic castration-resistant prostate cancer cells.
New study of artificial intelligence tools that analyze tumor images shows how they can make inaccurate predictions based on the institution that submitted the image
Tarsha Jones, Ph.D., principal investigator and an assistant professor of nursing at FAU’s Christine E. Lynn College of Nursing, has received the National Institute of Health (NIH) K01 Career Development Award, a five-year, $772,525 award for a project titled, “Decision Support for Multigene Panel Testing and Family Risk Communication among Racially/Ethnically Diverse Young Breast Cancer Survivors.”
A Roswell Park Comprehensive Cancer Center team reports new data on the promise of combining standard treatment for breast cancer with a particular form of cancer immunotherapy — dendritic-cell (DC) treatment vaccines.
The University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC) has earned renewal of its National Cancer Institute (NCI) designation as a Comprehensive Cancer Center for another five years. The prestigious distinction recognizes the cancer center’s high caliber of scientific leadership and robust programs in basic, clinical and population science research, placing it in the top echelon of cancer centers nationwide.
Bradley received a nearly $4 million grant from the National Cancer Institute to study ways to lessen the impacts of stress specifically on cancer caregivers who are also employed.
Zeynep Eroglu, M.D., assistant member of the Cutaneous Oncology Department at Moffitt Cancer Center, received the 2021 Cancer Clinical Investigator Team Leadership Award from the National Cancer Institute.
The Basser Center for BRCA at the Abramson Cancer Center of the University of Pennsylvania, the world’s first comprehensive center aimed at advancing research, treatment, and prevention of BRCA-related cancers, has announced Andre Nussenzweig, PhD, of the National Cancer Institute (NCI) as the recipient of the ninth annual Basser Global Prize. Nussenzweig serves as branch chief of the Laboratory of Genome Integrity in the NCI’s Center for Cancer Research.
Using Argonne National Laboratory’s Advanced Photon Source, researchers have determined the structure of an enzyme that plays a key role in the spread of cancer cells.
New research from the University of California, Irvine reveals how the circadian regulation of glucose production in the liver is lost during lung cancer progression, and how the resulting increase in glucose production may fuel cancer cell growth.
DALLAS – June 24, 2021 – Mutations in a gene related to HER2, a gene frequently implicated in breast cancers and a variety of other malignancies, can amplify activity that spurs tumor growth, a new study led by UT Southwestern researchers suggests. The findings, published online in Cancer Cell, could explain why many patients with HER2 mutations don’t respond to inhibitors that target this cancer driver and require other treatment.
Researchers report that about a quarter of localized prostate cancers may demonstrate immunologic traits that suggest a substantial number of patients with prostate cancer may benefit from immunotherapies.
A new blood test could signal whether treatment for metastatic HPV-positive throat cancer is working months earlier than standard imaging scans, allowing doctors to try alternatives sooner, initial results show.
A new University of Kentucky College of Medicine study will examine how policies that restrict the sale of flavored tobacco products including menthol cigarettes impact health disparities among vulnerable populations.
In a new study, a team of researchers uncovered new mechanisms underlying an important type of resistance to modern prostate cancer drugs called lineage plasticity, where castration-resistant prostate cancers undergo a deadly identity switch. They also outline a promising path to overcoming this form of resistance: BET bromodomain inhibitors.
In a bid to find or refine laboratory research models for cancer that better compare with what happens in living people, Johns Hopkins Medicine scientists report they have developed a new computer-based technique showing that human cancer cells grown in culture dishes are the least genetically similar to their human sources.
Just a small number of cells found in tumors can enable and recruit other types of cells nearby, allowing the cancer to spread to other parts of the body, report Georgetown Lombardi Comprehensive Cancer Center scientists. Working with their research collaborators, the scientists found that ‘enabler cells’ comprise about 20 percent or less of the cells in an aggressive tumor; their small numbers may account for why they are often missed when bulk tissue analyses are used to inform therapeutic decisions.
DALLAS – June 14, 2021 – Overweight cancer patients receiving immunotherapy treatments live more than twice as long as lighter patients, but only when dosing is weight-based, according to a study by cancer researchers at UT Southwestern Medical Center.
A new study published today in Cancer Discovery, a journal of the American Association for Cancer Research, reports findings that may change the understanding of how synovial sarcoma develops and spreads. The study was led by Kevin B. Jones, MD and Bradley R. Cairns, PhD from Huntsman Cancer Institute.
The National Cancer Institute (NCI) of the National Institutes of Health has granted over $4.2 million to launch the Cancer Epitope Database and Analysis Resource (CEDAR), led by La Jolla Institute for Immunology (LJI) Professors Alessandro Sette, Dr. Biol. Sci., and Bjoern Peters, Ph.D.
Perlmutter Cancer Center at NYU Langone Health is collaborating with more than 70 other National Cancer Institute (NCI)-designated cancer centers and partner organizations to issue a joint statement urging the nation’s physicians, parents and young adults to get the human papillomavirus (HPV) vaccination back on track.
Sanford Burnham Prebys has joined doctors & scientists across America at National Cancer Institute (NCI)-designated cancer centers & other organizations to issue a joint statement urging the nation’s physicians, parents & young adults to get the human papillomavirus (HPV) vaccination back on track.
As part of a unanimous effort on the part of the nation’s 71 National Cancer Institute (NCI)-designated cancer centers, Roswell Park Comprehensive Cancer Center is urging the nation’s physicians, parents and young adults to get cancer-preventing human papillomavirus (HPV) vaccination back on track.
Mayo Clinic Cancer Center has joined 71 National Cancer Institute-designated comprehensive cancer centers in calling on the nation's health care providers, parents and young adults to help get HPV vaccinations back on track. HPV causes several types of cancers, and nearly everyone gets infected with HPV by age 50.
The University of Kansas Cancer Center has partnered with 70 other National Cancer Institute (NCI)-designated cancer centers and partner organizations to issue a joint statement urging the nation’s physicians, parents and young adults to get the human papillomavirus (HPV) vaccination back on track.
MD Anderson researchers have developed a first-of-its-kind AI tool to identify rare groups of biologically important cells from the noise of large, complex single-cell datasets. The new tool, called SCMER, can help reserachers gain new insights across many applications.
A study led by scientists at Sanford Burnham Prebys Medical Discovery Institute has identified a tumor marker that may be used to predict which breast cancer patients will experience resistance to endocrine therapy. The research offers a new approach to selecting patients for therapy that targets HER2, a protein that promotes the growth of cancer cells, to help avoid disease relapse or progression of endocrine-sensitive disease.
U-M researchers have discovered the first immune stimulating long noncoding RNA Involved in the body's response to cancer, suggesting potential approaches to improve immunotherapy treatment.
In a new study published in JAMA Dermatology, Moffitt Cancer Center researchers report on the mutation profile of acral nevi and describe differences between acral nevi and acral melanoma.
Researchers at Huntsman Cancer Institute have found critical new insights into how cells defend against melanoma. In a report published in Nature Communications, the team describes how an enzyme called nicotinamide phosphoribosyltransferase, or NAMPT, initiates antitumor activity. The researchers suggest that new therapies strengthening this pathway in immune cells could be the foundation for more effective treatments against melanoma.
In a new article published in the journal Immunity, Moffitt Cancer Center researchers show that TIM-3 inhibits the STING signaling pathway in dendritic cells, thereby blocking their ability to elicit an immune response.